molecular biology
DNA Script Closes $200M Series C Financing With Completion of Second Tranche
Founded in 2014 by CEO Thomas Ybert, DNA Script is a life sciences technology company developing SYNTAX, which empowers scientists to print synthetic nucleic acids for genomics and molecular biology applications at the convenience of their lab bench. On-demand printing enables labs to iterate without waiting days or weeks to receive their genetic material from third-party service providers.
DNA Script Closes $200M Series C Financing With Completion of Second Tranche
DNA Script, a South San Francisco, CA-based pioneer in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, completed its Series C financing, raising $200m of new capital
SalioGen Therapeutics Closes $115M Series B Financing
Led by Ray Tabibiazar, M.D., chief executive officer and chairman, SalioGen has developed a Gene Coding platform designed to turn on, turn off or modify the function of any gene in the genome. Gene Coding is applied through SalioGen’s Exact DNA Integration Technology™ (EDIT™), which is based on mammal-derived genome engineering enzymes collectively called Saliogase™. With this portfolio of enzymes, the technology can integrate new DNA sequences of any length directly into a defined location in the genome, without the use of viral vectors. The Gene Coding platform is designed to address the limitations of current genetic medicine approaches, including gene editing and viral vector-based gene therapies, and to realize the potential of genetic medicines to reach broader patient populations.
https://www.finsmes.com/2022/01/saliogen-therapeutics-closes-115m-series-b-financing.html
Ambagon Therapeutics Raises $85M in Series A Funding
Led by CEO Scott Clarke, Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules. Ambagon applies deep knowledge of 14-3-3 proteins and a proprietary suite of drug discovery tools to create molecular glues that stabilize 14-3-3:target complexes. These molecular glue stabilizers amplify native biology to restore or inhibit target function, potentiate target activity, or promote or block target degradation. Ambagon’s initial focus is on oncology, with five programs in discovery.
Ambagon Therapeutics Raises $85M in Series A Funding - FinSMEs
Ambagon Therapeutics, a San Francisco CA-based biotechnology company, raised $85M in Series A funding
Virtue Diagnostics Raises $100M in Series B Funding
Led by Johnson Zhang, CEO, Virtue Diagnostics is a global, platform-based IVD (In Vitro Diagnostic) company focusing on providing affordable clinical solutions at all disease stages including very early screening, initial diagnosis, treatment monitoring and minimal residual disease management.
Virtue Diagnostics Raises $100M in Series B Funding - FinSMEs
Virtue Diagnostics, a Singapore and Shanghai, China-based IVD company focused on infectious disease, cancer, and chronic diseases, raised $100M in Series B funding
Accro Bioscience Raises Over $50M in Series B Funding
Led by Dr. Xiaohu Zhang, co-founder and CEO, Accro Bioscience was established in late 2017 and raised exclusive series A investment from Morningside Ventures. The company’s research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis, which are associated with major human diseases.
Its core R&D team has over 10 years of experience in biological research in regulated cell death and medicinal chemistry. Dr. Xiaohu Zhang, co-founder and CEO of Accro Bioscience, is a pharmaceutical industry veteran and previously served as the Executive Director at BioDuro/PDD China, Dr. Sudan He, co-founder, and scientific consultant at Accro, is a distinguished scholar.